Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Shimonishi, Atsushi, Ohashi, Kadoaki, Ninomiya, Kiichiro, Higo, Hisao, Kato, Yuka, Fujii, Masanori, Kubo, Toshio, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149432/
https://www.ncbi.nlm.nih.gov/pubmed/35702678
http://dx.doi.org/10.1159/000524326
_version_ 1784717208941756416
author Makimoto, Go
Shimonishi, Atsushi
Ohashi, Kadoaki
Ninomiya, Kiichiro
Higo, Hisao
Kato, Yuka
Fujii, Masanori
Kubo, Toshio
Ichihara, Eiki
Hotta, Katsuyuki
Tabata, Masahiro
Maeda, Yoshinobu
Kiura, Katsuyuki
author_facet Makimoto, Go
Shimonishi, Atsushi
Ohashi, Kadoaki
Ninomiya, Kiichiro
Higo, Hisao
Kato, Yuka
Fujii, Masanori
Kubo, Toshio
Ichihara, Eiki
Hotta, Katsuyuki
Tabata, Masahiro
Maeda, Yoshinobu
Kiura, Katsuyuki
author_sort Makimoto, Go
collection PubMed
description Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.
format Online
Article
Text
id pubmed-9149432
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-91494322022-06-13 Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report Makimoto, Go Shimonishi, Atsushi Ohashi, Kadoaki Ninomiya, Kiichiro Higo, Hisao Kato, Yuka Fujii, Masanori Kubo, Toshio Ichihara, Eiki Hotta, Katsuyuki Tabata, Masahiro Maeda, Yoshinobu Kiura, Katsuyuki Case Rep Oncol Case Report Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement. S. Karger AG 2022-05-05 /pmc/articles/PMC9149432/ /pubmed/35702678 http://dx.doi.org/10.1159/000524326 Text en Copyright © 2022 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Makimoto, Go
Shimonishi, Atsushi
Ohashi, Kadoaki
Ninomiya, Kiichiro
Higo, Hisao
Kato, Yuka
Fujii, Masanori
Kubo, Toshio
Ichihara, Eiki
Hotta, Katsuyuki
Tabata, Masahiro
Maeda, Yoshinobu
Kiura, Katsuyuki
Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
title Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
title_full Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
title_fullStr Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
title_full_unstemmed Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
title_short Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
title_sort successful and prompt treatment with tepotinib for lung adenocarcinoma harboring met exon 14 skipping mutation combined with lung abscess formation: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149432/
https://www.ncbi.nlm.nih.gov/pubmed/35702678
http://dx.doi.org/10.1159/000524326
work_keys_str_mv AT makimotogo successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT shimonishiatsushi successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT ohashikadoaki successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT ninomiyakiichiro successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT higohisao successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT katoyuka successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT fujiimasanori successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT kubotoshio successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT ichiharaeiki successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT hottakatsuyuki successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT tabatamasahiro successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT maedayoshinobu successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport
AT kiurakatsuyuki successfulandprompttreatmentwithtepotinibforlungadenocarcinomaharboringmetexon14skippingmutationcombinedwithlungabscessformationacasereport

Ejemplares similares